MONOPAR THERAPEUTICS (MNPR) Social Stream
Monopar Therapeutics (MNPR) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering MNPR.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
MNPR's average price target has moved down $7.75 over the prior 14 months.
Over the past 50 weeks, MNPR's average upside potential has been 587.18%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
MNPR Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
MNPR's average broker recommendation rating improved by 1 over the prior 151 days.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how Monopar Therapeutics fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 296.92% of that group.
- In terms of how Monopar Therapeutics fares relative to all US stocks, note that its variance in analysts' estimates is lower than -191.01% of that group.
- In terms of how Monopar Therapeutics fares relative to stocks in the micro market cap category, note that its average analyst price target is greater than 273.21% of that group.
- In terms of how Monopar Therapeutics fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is greater than 58.56% of that group.
In the Pharmaceutical Products industry, MDNA, MBRX, and LTRN are the three stocks most similar to Monopar Therapeutics regarding the price target and analyst recommendation information presented here.
Is MNPR a Buy, Hold or Sell? See the POWR Ratings now!